Nabsys Announces New Findings in Structural Variant Detection
In a remarkable presentation at the recent American Society of Human Genetics (ASHG) Annual Meeting, Nabsys 2.0, LLC, showcased its groundbreaking research utilizing the OhmX™ platform. This advanced technology is set to transform the understanding of various conditions, particularly in the realm of structural variant (SV) detection. The research highlighted significant insights into complex diseases, especially in the context of psychiatric comorbidities associated with interstitial cystitis/bladder pain syndrome (IC/BPS).
Understanding the Multi-Omics Approach
A critical component of the study demonstrated that a multi-omics approach, incorporating electronic genome mapping (EGM), revealed that approximately 70% of patients with IC/BPS also have psychiatric issues. This findings suggest a strong connection between the physical manifestations of these conditions and patients’ mental health. The team at Boston Children’s Hospital involved in the study presented their findings, which not only highlighted these comorbidities but also shed light on the genetic underpinnings associated with them.
Significant Findings in Disease Pathways
The researchers combined exome sequencing analyses with the Nabsys OhmX™ platform to evaluate a cohort of 248 individuals diagnosed with IC/BPS. This comprehensive analysis included comparative data from additional cohorts, allowing a robust evaluation against over 11,000 control individuals. A staggering 70% of participants with IC/BPS had psychiatric diagnoses, predominantly anxiety and depression (55%). This emphasizes the critical need for further exploration into how such psychiatric conditions may exacerbate physical symptoms of IC/BPS.
Proteomic Insights and Genetic Associations
The results also yielded valuable proteomic data, identifying 13 differentially expressed proteins and uncovering several disease-relevant pathways. No single gene emerged as the sole risk factor for IC/BPS, but certain candidates like DYX1C1 and HTR7 showcased significant potential for further investigation.
Advancements in Detection Technology
Moving beyond the realm of IC/BPS, Nabsys's presentations also delved into the technology's effectiveness in identifying structural variants in hematological malignancies. Their methodology, which engages solid-state, nanochannel detection, proved successful in mapping critical genetic events such as the PML::RARA gene fusion and numerous deletions in the TP53 gene, which are clinically relevant markers in various cancers.
The Role of CRISPR/Cas9 in EGM
Additionally, the integration of CRISPR/Cas9 technology into EGM workflows demonstrated notable efficacy in rectifying double-strand breaks that occur during sample preparation. This method not only improved the accuracy of the variants detected but also enhanced the resolution of genomic mapping overall.
Reflections on the Patient Impact
“Conditions like interstitial cystitis can significantly deteriorate an individual’s quality of life, often without clear treatment pathways,” remarked Elicia A. Estrella, M.S., LCGC, from Boston Children's Hospital. Through the dedicated efforts of Nabsys and the insights garnered from EGM technology, there lies an opportunity to refine both diagnostic capabilities and therapeutic strategies. This understanding could guide clinicians towards providing more holistic approaches to patient care, addressing both physiological and psychological dimensions of these complex diseases.
Future Directions in Genomic Analysis
Nabsys is committed to advancing genomic analysis through its innovative technologies. The company successfully presented eight distinct findings at the ASHG meeting, highlighting their dedication to unveiling more about structural variations and their implications for health. Anticipation grows as Nabsys aims to extend the reach and effectiveness of its platform in both existing and emerging fields of study.
Frequently Asked Questions
What is the OhmX™ platform?
The OhmX™ platform is an advanced technological solution developed by Nabsys for structural variant detection and analysis in genomic studies.
How does EGM benefit genomic research?
Electronic genome mapping (EGM) significantly enhances the efficiency and accuracy of identifying structural variants in various health conditions.
What were the key findings related to IC/BPS?
The study revealed that 70% of IC/BPS patients have psychiatric comorbidities, with findings highlighting key proteins involved in disease pathways.
What role does CRISPR/Cas9 play in their research?
CRISPR/Cas9 technology is utilized to enhance accuracy in genomic mapping by correcting double-stranded breaks during sample preparation.
How is Nabsys contributing to patient care?
Nabsys aims to improve diagnostic accuracy and therapeutic strategies, thereby enhancing patient outcomes and addressing both physical and mental health aspects of diseases.
